HOME >> MEDICINE >> NEWS
Potential new treatment for insulin-dependent diabetes

Scientists in Japan have found a way to improve on a promising diabetes treatment. In the October 3 issue of The Journal of Experimental Medicine, Masaru Taniguchi and colleagues report that transplanted insulin-producing cells survive better when the activation of a specific type of immune cell is blocked.

Insulin-dependent diabetes is caused by the destruction of the insulin-producing cells in the pancreas (called islet cells) by auto-reactive T cells. The loss of insulin results in an inability to control blood sugar levels. Transplantation of islet cells is an effective way to restore insulin production, but this therapy requires life-long immunosuppression of the patient. Even with immunosuppression, up to half of the transplanted cells are rapidly destroyed by the patient's own T cells.

Taniguchi's group used a mouse model to show that a subset of cells known as natural killer T (NKT) cells instigates the rapid destruction of the islet cells. NKT cells become activated -- likely in response to the stress of the transplant procedure -- and produce an inflammatory molecule called interferon (IFN)-gamma, which helps to activate the auto-reactive T cells. In mice that lack NKT cells or are unable to produce IFN-gamma, the transplanted cells survived.

The group went on to show that multiple doses of a drug (called alpha-galactosylceramide), which activates NKT cells in single doses, caused these cells to produce less IFN-gamma. The decreased IFN-gamma production protected the transplanted islet cells. The authors thus suggest that multiple doses of the same compound, currently in clinical trials in humans, might help prevent the early loss of transplanted islet cells in patients with insulin-dependent diabetes.


'"/>

Contact: Nickey Henry
henryn@rockefeller.edu
212-327-8366
Journal of Experimental Medicine
26-Sep-2005


Page: 1

Related medicine news :

1. Potential prostate cancer treatment improvements discovered by researchers at Cedars-Sinai
2. Potential heart benefit found in stem cells
3. Potential association between skin cancer cream and improvements of prematurely aged skin
4. Potential treatment for intracerebral hemorrhage under study
5. Potential pharmaceutical drugs in the field of cancer
6. Potential weak link between virus and liver cancer discovered
7. Spot on treatment for acne
8. New treatment boosts muscle function in myasthenia gravis
9. New treatment effective in counteracting cocaine-induced symptoms
10. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
11. Preventive treatments in elderly people needs rethinking

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to ... unique items from across the nation, this holiday-themed event will raise funds and awareness ... VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based workplace ... Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored at ... from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically ... announced three leadership team developments today:   ... ... Tom ... Veteran medical device executive Josh Stopek , PhD, who ...
Breaking Medicine Technology:
Cached News: